Your genes can impact how you respond to a GLP-1 In a study published in Genome Medicine , researchers found that about 10 percent of people carry certain variants of whats known as the PAM gene, and those individuals had a weaker blood sugar response to GLP-1based drugs compared to non-carriers
A licensed U.S
They do not replace thyroid hormone medication when needed
Protein triggers CCK and boosts satiety hormones like peptide YY, keeping you full for 3-4 hours
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial
These results suggest there is no excess cardiovascular risk with tirzepatide and are consistent with the improvements of numerous surrogate markers of cardiovascular health, including weight reduction, glycemic control with less hypoglycemia, blood pressure reduction, and improvements in the lipid profile
